
CORRIGENDUM

Type 2 inflammation in asthma — present in most, absent in many

John V. Fahy

Nature Reviews Immunology **15**, 57–65 (2015)

In the version of this article that was originally published, the targeted epitope of lebrikizumab was listed as “IL-4R α ” in Table 1 but this should be “IL-13 (IL-4R α -binding epitope)”. Also, for the main effects of lebrikizumab in human asthma trials, the citation of reference 44 should be reference 48. The author apologizes for these errors, which have now been corrected online.